The research progress of PD-1 channel inhibition in tumor treatment / 天津医药

ABSTRACT

Programmed death1 (PD-1) is mainly expressed on the surface of activated T cell. The combination between PD-1 and its legends PD-L1/PD-L2 activate downstream signaling pathways and negatively regulate T cell activation. Ab?normal increase expression of PD-L1 on tumor cell surface mediates the tumor immune escape. Inhibition of PD-1 signaling pathway contributes to antitumor effect of T cells. The development of this pathway inhibitors has become a hot spot for tu?mor immunotherapy. This article expounds the progress about antitumor effects mediated by PD-1 pathway inhibition from experiments in vivo or in vitro and clinical development of PD-1 pathway inhibitors, providing a new target for cancer immu?notherapy and theoretical and clinical basis for the clinical application of immunotherapy with traditional therapy methods.